Needham Reiterates Buy on Verrica Pharmaceuticals, Maintains $16 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a Buy rating on Verrica Pharmaceuticals (NASDAQ:VRCA) and maintained a $16 price target.
May 16, 2024 | 3:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Serge Belanger has reiterated a Buy rating on Verrica Pharmaceuticals and maintained a $16 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and the maintenance of a $16 price target by a reputable analyst suggests positive sentiment and confidence in the company's future performance, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100